The government is asking pharmaceutical companies to stockpile an additional 6-week supply of medicine, on top of their usual stock levels, in case normal supply routes through the European Union are disrupted.
The United Kingdom this week published a series on guidance documents on how to prepare for a scenario in which the United Kingdom exits the European Union with no deal struck, and several of those documents outlined serious impacts on the pharmaceutical industry.
In the event of a no-deal Brexit, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) says that, to ensure a continuous supply of necessary medicines, it will accept batch testing of medicines that are carried out in EU and European Economic Area (EEA) nations. For medicines manufactured in the European Union and EEA, the MHRA will accept the certification of a qualified person based in the country of manufacture without requiring additional certification.
Read more about Brexit and the pharmaceutical industry.
In a letter to the healthcare sector that accompanied release of the guidances, the Secretary of State for Health and Social Care, Matt Hancock, added that, to ensure that there is no disruption to the supply of medicine, the government is asking pharmaceutical companies to stockpile an additional 6-week supply of medicine, on top of their usual stock levels, in case normal supply routes through the European Union are disrupted. Hancock’s letter adds that the government is planning to bring medicines with short shelf-lives into the country by air freight. However, Hancock urged clinicians and community pharmacies not to stockpile drugs in their locations, nor to give patients longer supplies to keep at home.
Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars association, called these plans “Making the best of a bad job” in a statement. Smith added, “As we have consistently said, what is needed to ensure the supply of medicines to British patients is an agreement between the [United Kingdom] and the EU27 to allow the free flow of medicines and their components. Ideally, we want the [United Kingdom] to remain part of the European medicines regulatory environment, or more pragmatically a mutual recognition agreement to be agreed quickly.”
Additional information contained in the guidance documents noted that, post-Brexit, the MHRA would have to assume all functions currently handled by the European Medicines Agency for the regulation of drugs (an eventuality that would require changes to UK law), and pharmacovigilance efforts, currently conducted at an EU level, would become the sole responsibility of the MHRA.
The guidance also clarified that there will be no UK involvement in the new EU Clinical Trial Regulation, so there would be no UK access to the single portal for clinical trial data. UK—EU sharing of any type of data used for regulatory decisions on medicines would cease, and the United Kingdom would be required to develop a new system to receive regulatory submissions.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.